Core Insights - TTEC Holdings, Inc. reported a net loss of $170.5 million in Q4 2025, primarily due to a non-cash goodwill impairment charge of $205.4 million, despite a slight revenue increase of 0.4% to $570.0 million [2][4][9] - For the full year 2025, the company experienced a revenue decline of 3.2% to $2.137 billion, with a net loss of $185.1 million, although non-GAAP net income was $52.8 million, representing 2.5% of revenue [3][4][13] - The company is optimistic about 2026, projecting revenue between $2.005 billion and $2.055 billion, with a focus on improving EBITDA and operating income margins [19][20] Financial Performance - Q4 2025 revenue was $570.0 million, up 0.4% from $567.4 million in Q4 2024, with a positive foreign exchange impact of $4.0 million [9] - Adjusted EBITDA for Q4 2025 was $62.2 million, or 10.9% of revenue, compared to $50.9 million, or 9.0% of revenue in the prior year [8][9] - Full year 2025 adjusted EBITDA was $213.7 million, or 10.0% of revenue, an increase from $202.3 million, or 9.2% of revenue in 2024 [11][13] Segment Performance - TTEC Digital reported Q4 2025 revenue of $125.5 million, a 9.2% increase year-over-year, but faced a significant loss from operations of $200.0 million [21] - TTEC Engage had Q4 2025 revenue of $444.5 million, a 1.8% decrease from the previous year, but improved its income from operations to $27.4 million, or 6.2% of revenue [21] Cash Flow and Balance Sheet - Cash flow from operations in Q4 2025 was positive at $2.6 million, a recovery from a negative $1.1 million in Q4 2024, with full year cash flow from operations at $121.1 million compared to a negative $58.8 million in 2024 [14] - As of December 31, 2025, TTEC had cash and cash equivalents of $82.9 million and total debt of $908.0 million, resulting in a net debt position of $825.1 million [14][15] Business Outlook - The company aims to enhance its EBITDA and operating income in 2026, with a commitment to higher value transformational engagements across its segments [19][20] - TTEC's guidance for 2026 includes projected revenue of $2.030 billion and non-GAAP adjusted EBITDA of $230 million, indicating a focus on margin expansion [20][22][23]

LYNNWOOD, Wash., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Zumiez Inc. (NASDAQ: ZUMZ) today announced it will report fiscal 2025 fourth quarter and full year results on Thursday, March 12, 2026, following the closing of regular stock market trading hours. The Company will hold a conference call that day at 5:00 p.m. ET to review the results. To access the conference call, please pre-register using this link (Registration Link). Registrants will receive confirmation with dial-in details. The conference call will als ...

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outst ...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 20 ...

WEST PALM BEACH, FL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- AVAX One Technology Ltd. (Nasdaq: AVX) (“AVAX One” or the "Company"), today announced its participation at the upcoming Citizens Technology Conference being held March 2-3, 2026 at the Ritz-Carlton hotel in San Francisco, CA. AVAX One’s management team will host 1x1 investor meetings throughout the day on Monday, March 2, 2026. The Company will also participate in the “Digital Asset Treasuries: Creating Value Beyond Spot Exposure” panel at 1:00 PM PT on ...

Exceeds high-end of second-quarter guidance on revenue and profitability metrics Second Quarter Highlights Revenue grew 26% year-over-year to $815.8 millionAnnual Recurring Revenue ("ARR") grew 25% year-over-year to $3,359 millionOperating cash flow grew 14% year-over-year to $204.1 millionFree cash flow grew 18% year-over-year to $169.1 million SAN JOSE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quart ...

Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total reve ...

ROSEMONT, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation (“Wintrust” or the “Company”) (Nasdaq: WTFC) will present at the RBC Capital Markets Global Financial Institutions Conference to be held on March 10-11, 2026. Wintrust management will participate in a question-and-answer session that is scheduled to begin at approximately 1:20 PM Eastern Time on March 10, 2026. This event will be available via an audio webcast and may be accessed at https://kvgo.com/rbc-2026-global-financial-in ...

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a gl ...

Guides to record Q1 revenue of $185M - $200M, representing year-on-year growth of 57% at the midpoint of the rangeLONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab”, “the Company”, “we,” “us,” or “our”), a global leader in launch services and space systems, today shared the financial results for fiscal fourth quarter and full year ended December 31, 2025. Rocket Lab founder and CEO, Sir Peter Beck, said: “2026 was a record-breaking year for Rocket Lab f ...